Sequenom Inc.
Funding rounds
2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2015 | $85 M | Issued in a merger or acquisition | $50 to $250 million | debt, options | SEC | |
| May 2010 | $52 M | No. 2 | $50 to $250 million | equity | SEC | |
| Dec 2009 | $2 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Sequenom Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2015).
SEC Form D · Jun 2015
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2015
That is all the official record says: Sequenom Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: the address on record now leads to another company's site.
Investors#
No investor of Sequenom Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 27 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Carolyn F. Beaver | Executive officer | Jun 2015 |
| Daniel S. Grosu | Executive officer | Jun 2015 |
| Dirk van den Boom | Executive officer | Jun 2015 |
| Jeff M. Linton | Executive officer | Jun 2015 |
| Robin S. Weiner | Executive officer | Jun 2015 |
| William S. Welch | Executive officer | Jun 2015 |
| Alexander T. Monko | Executive officer | May 2010 |
| Alisa T. Judge | Executive officer | May 2010 |
| Allen T. Bombard | Executive officer | May 2010 |
| Charles R. Cantor | Executive officer | May 2010 |
| Clarke T. Neumann | Executive officer | May 2010 |
| Harry F. Hixson | Executive officer | May 2010 |
| Larry T. Myres | Executive officer | May 2010 |
| Paul W. Maier | Executive officer | May 2010 |
| Ronald M. Lindsay | Executive officer | May 2010 |
| Shawn T. Marcell | Executive officer | May 2010 |
| Gary T. Riordan | Executive officer | Dec 2009 |
| Charles M. Slacik | Director | Jun 2015 |
| David M. Pendarvis | Director | Jun 2015 |
| Dirk van den Boom | Director | Jun 2015 |
| John A. Fazio | Director | Jun 2015 |
| Kenneth F. Buechler | Director | Jun 2015 |
| Myla S. Lai-Goldman | Director | Jun 2015 |
| Richard A. Lerner | Director | Jun 2015 |
| Ronald M. Lindsay | Director | Jun 2015 |
| William S. Welch | Director | Jun 2015 |
| Charles R. Cantor | Director | May 2010 |
| Ernst-Gunter F. Afting | Director | May 2010 |
| Harry F. Hixson | Director | May 2010 |
| Kathleen W. Wiltsey | Director | May 2010 |
About
American life sciences company.